April 2, 2026

Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis: Unveiling a Potential 184% Upside in Biotech Innovation

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), a clinical-stage biopharmaceutical company, is making waves in the healthcare sector, capturing investor attention with its impressive potential for upside. With a current market capitalization..

Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 279% Potential Upside in the Biotech Space

Candel Therapeutics, Inc. (NASDAQ: CADL) is capturing the attention of the biotech investment community with a compelling investment narrative centered on its promising cancer immunotherapy pipeline. With a current market..

Zhengye Biotechnology Holding L (ZYBT): Navigating Challenges with a Focus on Veterinary Vaccines in China

Investors in the healthcare sector might find Zhengye Biotechnology Holding L (ZYBT) an intriguing yet challenging prospect due to its niche focus on veterinary vaccines. Based in Jilin, China, the..

Outset Medical, Inc. (OM) Stock Analysis: Exploring a 173% Potential Upside with Innovative Hemodialysis Solutions

Outset Medical, Inc. (OM), a promising player in the medical devices sector, might just be the opportunity investors are looking for, given its substantial potential upside of 173.44%. Specializing in..

ClearPoint Neuro Inc. (CLPT) Stock Analysis: Unpacking the 173.52% Potential Upside Amidst Robust Revenue Growth

ClearPoint Neuro Inc. (NASDAQ: CLPT), a pioneering entity in the healthcare sector, is making waves in the medical devices industry with its innovative platform for minimally invasive brain surgeries. With..

Rigel Pharmaceuticals, Inc. (RIGL): Investor Outlook with 86% Potential Upside

For investors seeking opportunities in the biotechnology sector, Rigel Pharmaceuticals, Inc. (RIGL) offers a compelling prospect with its impressive potential upside of 86.18%. The company, headquartered in South San Francisco,..

TotalEnergies SE (TTE) Stock Analysis: Balancing a Robust Dividend Yield with Modest Growth Potential

TotalEnergies SE (NYSE: TTE), a major player in the integrated oil and gas sector, offers a compelling proposition for investors seeking exposure to the energy market with a robust dividend..

NANO-X IMAGING LTD (NNOX) Stock Analysis: Potential 207% Upside Sparks Investor Interest

For investors keeping a keen eye on the healthcare sector, particularly the medical devices industry, Nano-X Imaging Ltd. (NASDAQ: NNOX) stands out as a compelling opportunity. Based in Israel, this..

Erasca, Inc. (ERAS) Stock Analysis: A Promising Biotech with Analyst Consensus and Growth Potential

Erasca, Inc. (ERAS), a clinical-stage biotechnology company, is gaining traction in the healthcare sector with its focus on precision oncology. Specializing in the development of therapies targeting RAS/MAPK pathway-driven cancers,..

Mereo BioPharma Group (MREO) Stock Analysis: Unpacking a 423% Potential Upside

For investors with a keen interest in the biotechnology sector, Mereo BioPharma Group plc (NASDAQ: MREO) presents a fascinating opportunity. This London-based biopharmaceutical company, with a market capitalization of $52.67..

Gene therapy moves rare disease treatment closer to the root cause

Gene therapy is gaining investor attention because it offers a more direct way to treat rare genetic diseases, while also bringing important questions around access, cost and long-term evidence...

Baillie Gifford Japan Trust underperforms TOPIX in interim 2026 results

Interim results for the six months to 28 February 2026 show Baillie Gifford Japan Trust delivered positive NAV and share price returns, but lagged the benchmark, while continuing share buybacks..

The Merchants Trust reports 2026 final results with 18.9% NAV total return

The Merchants Trust said NAV total return was 18.9% for the year ended 31 January 2026 and proposed a total dividend of 29.5p, marking its 44th consecutive annual increase...

Atalaya Mining acquires 7.3% stake in Lara Exploration for C$13.5 million

Atalaya Mining has acquired 4.5 million Lara Exploration shares through a private placement for C$13.5 million, giving it an approximate 7.3% stake. Lara plans to use the proceeds to advance..

SSE updates market with higher FY2025/26 EPS guidance and continued investment growth

Ahead of full-year results on 28 May 2026, SSE said it expects adjusted EPS of 147–152 pence for the year ended 31 March 2026. The company also reported a sharp..

Smiths Group finalises DRC Heat Transfer purchase to strengthen Flex-Tek

Smiths has completed its acquisition of DRC Heat Transfer, adding complementary thermal products and solutions to Flex-Tek and strengthening its position in growing markets such as backup power and mission-critical..

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim..

Firering reports stronger Limeco output as Kiln 2 exceeds 70 tonnes per day

Firering Strategic Minerals said production at its Limeco lime project in Zambia continues to improve, with Kiln 2 now averaging more than 70 tonnes per day during its optimisation phase...

Cizzle Biotechnology secures up to £250,000 funding facility to support CIZ1B test launch

Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial..

Supermarket Income REIT PLC (SUPR.L) Investor Outlook: High Dividend Yield and Potential Upside

Supermarket Income REIT PLC (SUPR.L) stands out in the Real Estate Investment Trust (REIT) sector, particularly in the retail niche, for its strategic focus on grocery properties. As a leader..

Search

Funds

April 2, 2026

Gene therapy moves rare disease treatment closer to the root cause

Gene therapy is gaining investor attention because it offers a more direct way to treat rare genetic diseases, while also bringing important questions around access, cost and long-term evidence...

Baillie Gifford Japan Trust underperforms TOPIX in interim 2026 results

Interim results for the six months to 28 February 2026 show Baillie Gifford Japan Trust delivered positive NAV and share price returns, but lagged the benchmark, while continuing share buybacks and adding new growth holdings...

The Merchants Trust reports 2026 final results with 18.9% NAV total return

The Merchants Trust said NAV total return was 18.9% for the year ended 31 January 2026 and proposed a total dividend of 29.5p, marking its 44th consecutive annual increase...

Atalaya Mining acquires 7.3% stake in Lara Exploration for C$13.5 million

Atalaya Mining has acquired 4.5 million Lara Exploration shares through a private placement for C$13.5 million, giving it an approximate 7.3% stake. Lara plans to use the proceeds to advance the Planalto copper-gold project in Brazil and for general corporate purposes...

SSE updates market with higher FY2025/26 EPS guidance and continued investment growth

Ahead of full-year results on 28 May 2026, SSE said it expects adjusted EPS of 147–152 pence for the year ended 31 March 2026. The company also reported a sharp rise in networks investment, renewables output of around 14.5 TWh and capital investment of about £3.5bn...

Smiths Group finalises DRC Heat Transfer purchase to strengthen Flex-Tek

Smiths has completed its acquisition of DRC Heat Transfer, adding complementary thermal products and solutions to Flex-Tek and strengthening its position in growing markets such as backup power and mission-critical applications...

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit...

Firering reports stronger Limeco output as Kiln 2 exceeds 70 tonnes per day

Firering Strategic Minerals said production at its Limeco lime project in Zambia continues to improve, with Kiln 2 now averaging more than 70 tonnes per day during its optimisation phase...

Cizzle Biotechnology secures up to £250,000 funding facility to support CIZ1B test launch

Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial launch of its CIZ1B biomarker test in North America, expansion in the UK and Europe, and ongoing clinical work with Moffitt Cancer Center...
Search

Funds

April 2, 2026

FTSE 100

Funds